Skip to main content
EJNMMI Research

Table 2 Performance status and baseline PSA level as well as PSA changes 8 weeks after therapy

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Number

ECOG1

ECOG2

Baseline PSA (ng/ml)

PSA2 (ng/ml)

PSA change (%)

1

1

1

226

529

134.7

2

1

1

334

243

−27.2

3

2

2

376

141

−62.5

4

1

1

853

590a

−30.8

5

1

1

148

46

−68.9

6

0

0

20

5

−75.0

7

1

1

263

355

35.0

8

1

1

790

293

−62.9

9

1

1

379

58

−84.7

10

3

2

5

21

320.0

  1. ECOG1 baseline Eastern Cooperative Oncology Group performance status, ECOG2 Eastern Cooperative Oncology Group performance status 2 months after therapy, PSA prostatic specific antigen, PSA2 prostatic specific antigen 2 months after therapy
  2. a4 weeks after Tx, PSA decreased to 71 ng/ml
Back to article page